Sequential Treatment Strategy for Metastatic Colorectal Cancer

NCT01878422 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

376

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: Arm A: FOLFIRI or FOLFOX + Bevacizumab
DRUG: Arm B: FOLFIRI or FOLFOX
DRUG: Arm D: FOLFIRI or FOLFOX plus CETUXIMAB
DRUG: Arm F: FOLFIRI or FOLFOX plus BEVACIZUMAB and CETUXIMAB

Sponsor

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS